Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Telix Pharmaceuticals Limited

Capitalization 3.73B 2.63B 2.27B 2.05B 1.96B 3.56B 242B 24.16B 9.69B 116B 9.86B 9.65B 415B P/E ratio 2026 *
-1,470x
P/E ratio 2027 * 90.8x
Enterprise value 4.19B 2.95B 2.55B 2.3B 2.2B 4B 272B 27.14B 10.88B 130B 11.08B 10.84B 467B EV / Sales 2026 *
3.09x
EV / Sales 2027 * 2.63x
Free-Float
58.65%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Telix Pharmaceuticals Limited

1 day+7.84%
1 week+12.70%
Current month+10.00%
1 month+11.56%
3 months-23.18%
6 months-20.41%
Current year-1.79%
1 week 9.35
Extreme 9.35
11.62
1 month 8.26
Extreme 8.26
11.62
Current year 8.26
Extreme 8.26
11.99
1 year 8.26
Extreme 8.26
29.72
3 years 6.51
Extreme 6.51
31.97
5 years 3.55
Extreme 3.55
31.97
10 years 0.46
Extreme 0.46
31.97
Manager TitleAgeSince
Chief Executive Officer 51 2017-01-02
Director of Finance/CFO 60 2022-07-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 51 2017-01-02
Chairman 66 2026-02-02
Director/Board Member 68 2018-06-18
Change 5d. change 1-year change 3-years change Capi.($)
+7.84%+12.70%-60.23%+52.57% 2.44B
+0.36%-3.16%-7.79%-6.03% 44.96B
+1.84%+3.66%+26.89%+42.40% 33.54B
+0.98%-13.63%+16.43%+43.10% 30.24B
-2.71%-0.69%-8.49%-12.42% 29.97B
+0.03%-0.57%+171.37%+381.31% 19.78B
-0.03%+0.34%+73.70%+125.99% 14.73B
-1.59%+1.13%+39.49%+168.29% 13.58B
+1.01%-2.90%+22.89%+1.23% 12.97B
+0.08%-4.05%+134.25%+122.25% 12.45B
Average +0.79%-1.11%+40.85%+91.87% 21.46B
Weighted average by Cap. +0.18%-1.63%+35.53%+71.88%

Financials

2026 *2027 *
Net sales 1.36B 955M 824M 744M 713M 1.3B 88.01B 8.79B 3.52B 42.1B 3.59B 3.51B 151B 1.6B 1.13B 976M 881M 844M 1.53B 104B 10.4B 4.17B 49.85B 4.25B 4.15B 179B
Net income -2.31M -1.63M -1.4M -1.27M -1.21M -2.21M -150M -14.95M -6M -71.66M -6.1M -5.97M -257M 31.92M 22.5M 19.41M 17.53M 16.8M 30.53M 2.07B 207M 82.98M 992M 84.46M 82.65M 3.56B
Net Debt 460M 324M 279M 252M 242M 440M 29.85B 2.98B 1.19B 14.28B 1.22B 1.19B 51.24B 490M 345M 298M 269M 258M 469M 31.81B 3.18B 1.27B 15.22B 1.3B 1.27B 54.61B
Logo Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.
Employees
1,152
Date Price Change Volume
26-03-10 11.00 $ +7.84% 4,690,000
26-03-09 10.20 $ -5.12% 3,307,656
26-03-06 10.75 $ +6.54% 3,725,239
26-03-05 10.09 $ +6.55% 1,821,915
26-03-04 9.470 $ -4.05% 5,164,455
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
10.20AUD
Average target price
22.92AUD
Spread / Average Target
+124.68%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW